Atossa Therapeutics' COVID-19 Nasal Spray Safe In Early-Stage Study

Atossa Therapeutics Inc (NASDAQ: ATOS) announces final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19.
The treatment was considered to be safe and well-tolerated at two different dose levels over 14 days.
The final analysis indicates that there were no serious adverse events, no discontinuations, no bronchospasm.
Only one of the 32 subjects in the study experienced moderate adverse events, and all other adverse events were considered mild.
An additional pre-clinical study is expected to start this quarter.
Price Action: ATOS surged 8.6% at $3.02 on the last check Thursday.